文献速递乳腺技术与安全PETMR

18F-FDG专用乳腺PET作为乳腺MRI的补充用于评估新辅助化疗早期反应

18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy.
PubMed 文献 · Radiol Imaging Cancer · 2024-01-01

前瞻性分析20例参与者22个浸润性乳腺癌病灶,在新辅助化疗前及3周后行18F-FDG专用乳腺PET和乳腺动态增强MRI,比较肿瘤代谢与灌注定量指标;高Ki-67肿瘤基线SUVmean和SUVpeak更高,化疗3周后dbPET多项代谢指标及MRI的SERpeak、FTV下降,dbPET对早期变化敏感并提供MRI之外的补充信息。

要点

  • 高Ki-67肿瘤基线SUVmean和SUVpeak更高,提示增殖活跃者代谢更旺。
  • 新辅助化疗3周后dbPET的SUVmax、SUVmean、SUVpeak、TLG均下降。
  • dbPET可补充DCE MRI信息,可能有助于疗效评估。

核心结论

  • 18F-FDG dbPET对新辅助化疗早期变化敏感,并提供DCE MRI之外的补充信息,可能有助于疗效评估。

关键影像表现/征象

  • 高Ki-67肿瘤基线SUVmean较高,差值5.1(P=0.01)。
  • 高Ki-67肿瘤基线SUVpeak较高,差值5.5(P=0.04)。
  • 化疗3周后SUVmax较基线下降,伪中位差值-6.2(95%CI -10.2至-2.6;P<0.001)。
  • 化疗3周后SUVmean下降-2.6(95%CI -4.9至-1.3;P<0.001),SUVpeak下降-4.2(95%CI -6.9至-2.3;P<0.001)。
  • 化疗3周后TLG下降-29.1 mL3(95%CI -71.4至-6.8;P=0.005),MRI的SERpeak下降-1.0(95%CI -1.3至-0.2;P=0.02),FTV下降-11.6 mL3(95%CI -22.2至-1.7;P=0.009)。

诊断标准与关键数值

  • 反应组较无反应组SUVmax百分比变化差值为-34.3%(95%CI -55.9%至1.5%;P=0.06)。
  • 反应组较无反应组PEpeak百分比变化差值为-42.4%(95%CI -110.5%至8.5%;P=0.08)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To compare quantitative measures of tumor metabolism and perfusion using fluorine 18 (18F) fluorodeoxyglucose (FDG) dedicated breast PET (dbPET) and breast dynamic contrast-enhanced (DCE) MRI during early treatment with neoadjuvant chemotherapy (NAC). Materials and Methods Prospectively collected DCE MRI and 18F-FDG dbPET examinations were analyzed at baseline (T0) and after 3 weeks (T1) of NAC in 20 participants with 22 invasive breast cancers. FDG dbPET-derived standardized uptake value (SUV), metabolic tumor volume, and total lesion glycolysis (TLG) and MRI-derived percent enhancement (PE), signal enhancement ratio (SER), and functional tumor volume (FTV) were calculated at both time points. Differences between FDG dbPET and MRI parameters were evaluated after stratifying by receptor status, Ki-67 index, and residual cancer burden. Parameters were compared using Wilcoxon signed rank and Mann-Whitney U tests. Results High Ki-67 tumors had higher baseline SUVmean (difference, 5.1; P = .01) and SUVpeak (difference, 5.5; P = .04). At T1, decreases were observed in FDG dbPET measures (pseudo-median difference T0 minus T1 value [95% CI]) of SUVmax (-6.2 [-10.2, -2.6]; P < .001), SUVmean (-2.6 [-4.9, -1.3]; P < .001), SUVpeak (-4.2 [-6.9, -2.3]; P < .001), and TLG (-29.1 mL3 [-71.4, -6.8]; P = .005) and MRI measures of SERpeak (-1.0 [-1.3, -0.2]; P = .02) and FTV (-11.6 mL3 [-22.2, -1.7]; P = .009). Relative to nonresponsive tumors, responsive tumors showed a difference (95% CI) in percent change in SUVmax of -34.3% (-55.9%, 1.5%; P = .06) and in PEpeak of -42.4% (95% CI: -110.5%, 8.5%; P = .08). Conclusion 18F-FDG dbPET was sensitive to early changes during NAC and provided complementary information to DCE MRI that may be useful for treatment response evaluation. Keywords: Breast, PET, Dynamic Contrast-enhanced MRI Clinical trial registration no. NCT01042379 Supplemental material is available for this article. © RSNA, 2024.

来源:Radiol Imaging Cancer,查看原文。版权归原作者所有。

引用

  1. Diwanji D, Onishi N, Hathi DK, et al. 18F-FDG Dedicated Breast PET Complementary to Breast MRI for Evaluating Early Response to Neoadjuvant Chemotherapy. Radiol Imaging Cancer. 2024. PMID: 38551406. doi:10.1148/rycan.230082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。